CA2318029A1 - Apo-2 ligand - Google Patents

Apo-2 ligand Download PDF

Info

Publication number
CA2318029A1
CA2318029A1 CA002318029A CA2318029A CA2318029A1 CA 2318029 A1 CA2318029 A1 CA 2318029A1 CA 002318029 A CA002318029 A CA 002318029A CA 2318029 A CA2318029 A CA 2318029A CA 2318029 A1 CA2318029 A1 CA 2318029A1
Authority
CA
Canada
Prior art keywords
ligand
apo
antibodies
believed
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002318029A
Other languages
French (fr)
Other versions
CA2318029C (en
Inventor
Avi J. Ashkenazi
Robert F. Kelley
Mark P. O'connell
Robert M. Pitti
Ralph H. Schwall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech, Inc.
Avi J. Ashkenazi
Robert F. Kelley
Mark P. O'connell
Robert M. Pitti
Ralph H. Schwall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., Avi J. Ashkenazi, Robert F. Kelley, Mark P. O'connell, Robert M. Pitti, Ralph H. Schwall filed Critical Genentech, Inc.
Publication of CA2318029A1 publication Critical patent/CA2318029A1/en
Application granted granted Critical
Publication of CA2318029C publication Critical patent/CA2318029C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

A novel cytokine, designated Apo-2 ligand, which induces mammalian cancer cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
CA002318029A 1998-01-15 1999-01-15 Apo-2 ligand Expired - Lifetime CA2318029C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US788698A 1998-01-15 1998-01-15
US09/007,886 1998-01-15
US6053398A 1998-04-15 1998-04-15
US09/060,533 1998-04-15
PCT/US1999/001039 WO1999036535A1 (en) 1998-01-15 1999-01-15 Apo-2 ligand

Publications (2)

Publication Number Publication Date
CA2318029A1 true CA2318029A1 (en) 1999-07-22
CA2318029C CA2318029C (en) 2009-05-19

Family

ID=26677483

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318029A Expired - Lifetime CA2318029C (en) 1998-01-15 1999-01-15 Apo-2 ligand

Country Status (13)

Country Link
US (1) US6740739B1 (en)
EP (2) EP2017341A3 (en)
JP (2) JP2002508962A (en)
AT (1) ATE411385T1 (en)
AU (1) AU2325199A (en)
CA (1) CA2318029C (en)
CY (1) CY1108681T1 (en)
DE (1) DE69939732D1 (en)
DK (1) DK1045906T3 (en)
ES (1) ES2316182T3 (en)
HK (1) HK1032603A1 (en)
PT (1) PT1045906E (en)
WO (1) WO1999036535A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US20040048340A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
NZ537920A (en) * 1999-06-28 2006-10-27 Genentech Inc An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand
IL161051A0 (en) * 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
CN1313611C (en) * 2002-02-22 2007-05-02 中国人民解放军第二军医大学 Novel tumor wilting matter 2 ligand gene, its expressed tumor wilting matter and its preparation method
JP4574350B2 (en) * 2002-06-24 2010-11-04 ジェネンテック， インコーポレイテッド APO-2 ligand / TRAIL variant and methods of use thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
ES2365719T3 (en) * 2004-08-06 2011-10-10 Genentech, Inc. TESTS AND PROCEDURES USING BIOMARKERS.
AU2012200601B2 (en) * 2004-08-06 2012-10-11 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20100150931A1 (en) * 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
JP2014513128A (en) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド Vascular disruptors and their use
EP2752429B1 (en) 2011-09-16 2017-03-01 Beijing Sunbio Biotech Co. Ltd. Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
SI2970473T1 (en) 2013-03-14 2017-10-30 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US9914761B2 (en) 2014-07-10 2018-03-13 Washington University Oligomers for TNF superfamily inhibition
UA126897C2 (en) 2015-12-01 2023-02-22 Генмаб Б.В. Anti-dr5 antibodies and methods of use thereof
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
PL3565828T3 (en) 2017-01-05 2022-04-04 Kahr Medical Ltd. A sirp1 alpha-41bbl fusion protein and methods of use thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human lymphotoxin and methods for its recombinant production
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (en) 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. 780 t-dna gene transcription activator
DE3889546T2 (en) 1987-12-21 1994-09-08 Univ Toledo TRANSFORMATION OF Germinating PLANT SEEDS WITH THE HELP OF AGROBACTERIUM.
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
DK168302B1 (en) 1989-06-29 1994-03-07 Danisco Method of introducing molecules, especially genetic material into plant cells
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69405102T2 (en) 1993-06-03 1998-01-15 Therapeutic Antibodies Inc ANTIBODY FRAGMENTS IN THERAPY
EP0723556A4 (en) 1993-10-14 2003-03-19 Immunex Corp Fas antagonists and uses thereof
WO1995011301A1 (en) 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
DE69635480T2 (en) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks APOPTOSIS INDUCTIVE CYTOKIN
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP2000515727A (en) 1996-06-07 2000-11-28 アムジエン・インコーポレーテツド Tumor necrosis factor-related polypeptide
KR20020056565A (en) 2000-12-29 2002-07-10 황규언 Three-dimensional structure of human derived apoptotic factor and receptor thereof by X-ray chrystallography and TRAIL deletion mutant protein
US20020115613A1 (en) 2001-02-16 2002-08-22 Kumar M. Vijay Treatment of prostate cancer

Also Published As

Publication number Publication date
DE69939732D1 (en) 2008-11-27
EP1045906A1 (en) 2000-10-25
WO1999036535A9 (en) 2000-03-02
JP2002508962A (en) 2002-03-26
AU2325199A (en) 1999-08-02
US6740739B1 (en) 2004-05-25
CA2318029C (en) 2009-05-19
WO1999036535A1 (en) 1999-07-22
EP1045906B1 (en) 2008-10-15
ES2316182T3 (en) 2009-04-01
EP2017341A3 (en) 2009-04-08
EP2017341A2 (en) 2009-01-21
PT1045906E (en) 2009-01-27
DK1045906T3 (en) 2009-02-16
JP2010246560A (en) 2010-11-04
CY1108681T1 (en) 2014-04-09
ATE411385T1 (en) 2008-10-15
HK1032603A1 (en) 2001-07-27

Similar Documents

Publication Publication Date Title
CA2241572A1 (en) Apo-2 ligand
CA2318029A1 (en) Apo-2 ligand
AU574568B2 (en) Method of reducing the permeability to water of subteranean sandstone
AU4232696A (en) Novel embryonic cell populations and methods to isolate such populations
AU2575701A (en) Sugarbeet regeneration and transformation
AU4346085A (en) Treatment of refractory surface to enhance resistance to attack by al
CA2070979A1 (en) Sequence specific dna binding by p53
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
CA2295306A1 (en) Dna polymerase-related factors
AU588981B2 (en) Improvements relating to the production of beer
AU578325B2 (en) Vertical cooker with cooking water recycling
DE69841176D1 (en) Rtd receptor
CA2140736A1 (en) A thixotropic fluid for well insulation
AU7574394A (en) TNF inhibitors
WO1999001551A3 (en) Novel inhibitor of cellular proliferation
EP0315987A3 (en) Improved organophilic clay suspension medium
EP0216934A4 (en) Novel tumor necrosis factor-inducing substance originating in acid-fast bacteria.
WO2001000854A3 (en) Chimeric proteins mediating targeted apoptosis
AU584102B2 (en) Method of increasing the volume yield of exfoliated vermiculite
AU569950B2 (en) Suppressing algal growth in solar ponds
WO2001040443A3 (en) Method for producing adherent animal cells
EP0233257A4 (en) Method of attaching biological substances to solid substrates.
RATE High Coupon Bonds Low Coupon Bonds Factor Loadings Factor Loadings for the Second for the Second Portfolio Common Factor Portfolio Common Factor
Kellar BIOCHEMICAL QUANTITATION OF GRANULOCYTE-SPECIFIC PROTEINS IN LIQUID CULTURES OF MURINE BONE MARROW STIMULATED BY COLONY STIMULATING ACTIVITY.
PL254284A1 (en) Cast iron inocculant in the form of pellets,bricks or briquettes

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190115